Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development (Hardcover, 2005)

Part I. Introduction Cardiac Safety of Noncardiac Drugs: Historical Recollections Raymond John Lipicky Part II. Preclinical and Pharmacogenomic Cardiac Safety Evaluations Molecular Physiology of Ion Channels That Control Cardiac Repolarization Jeanne M. Nerbonne and Robert S. Kass Cellular, Molecular, and Pharmacologic Mechanisms Underlying Drug-Induced Cardiac Arrhythmogenesis Charles Antzelevitch hERG Assay, QT Liability, and Sudden Cardiac Death Arthur M. Brown Pharmacogenomics in Drug Development: When and How to Apply Richard Judson and Arthur J. Moss Part III. Clinical Methodologies and Technical Aspects of Assessing Cardiac Safety of Investigational Drugs: Focus on Cardiac Repolarization Assessment of Ventricular Repolarization From Body-Surface ECGs in Humans Jean-Philippe Couderc and Wojciech Zareba ECG Acquisition and Signal Processing: 12-Lead ECG Acquisition Justin L. Mortara Digital 12-Lead Holter vs Standard Resting Supine Electrocardiogram for the Assessment of Drug-Induced QTc Prolongation: Assessment by Different Recording and Measurement Methods Nenad Sarapa Holter Monitoring for QT: The RR Bin Method in Depth Fabio Badilini and Pierre Maison-Blanche\n Part IV. Application of Electrocardiology in Clinical Research Fundamentals of ECG Interpretation in Clinical Research and Cardiac Safety Assessment Ihor Gussak, Robert Kleiman, and Jeffrey S. Litwin Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs Joel Morganroth Use of ECGs in Support of Cardiac Safety in Phase II and III Clinical Trials Martin P. Bedigian Cardiac Arrhythmia Assessment in Phase IV Clinical Studies Gerald A. Faich and Annette Stemhagen Statistical Analysis Plans for ECG Data: Controlling the Intrinsic and Extrinsic Variability in QT Data Alan S. Hollister and Timothy H Montague Interpretation of Clinical ECG Data: Understanding the Risk From Non-Antiarrhythmic Drugs Rashmi R. Shah Part V. Regulatory Considerations The FDA's Digital ECG Initiative and Its Impact on Clinical Trials Barry D. Brown Quality Control and Quality Assurance for Core ECG Laboratories Amy M. Annand-Furlong ECG Digital Communities and Electronic Reporting of Cardiac Safety Data: New Technologies for Reporting Digital ECG Data in Clinical Research Settings Scott Grisanti and Robert Brown Index